Liquidia (NASDAQ:LQDA) Director Stephen Bloch Sells 235,477 Shares of Stock

Liquidia Corporation (NASDAQ:LQDA) Director Stephen Bloch sold 235,477 shares of the stock in a transaction on Monday, October 5th. The stock was sold at an average price of $27.13, for a total value of $6,388,491.01. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Liquidia Stock Performance

Shares of Liquidia stock traded up $0.77 during trading hours on Wednesday, reaching $26.68. The company had a trading volume of 6,960,401 shares, compared to its average volume of 2,033,381. The firm has a market cap of $2.39 billion, a PE ratio of 19.47 and a beta of 0.61. Liquidia Corporation has a one year low of $21.94 and a one year high of $93.61. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.31 and a quick ratio of 2.12. The business has a fifty day simple moving average of $69.27 and a 200 day simple moving average of $62.07.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings data on Wednesday, August 12th. The company reported $0.74 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). The company had revenue of $171.68 million for the quarter, compared to the consensus estimate of $168.48 million. Liquidia had a net margin of 30.74% and a return on equity of 149.65%. The business’s revenue for the quarter was up 1842.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.49) earnings per share. On average, analysts anticipate that Liquidia Corporation will post 2.1 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Liquidia

Several hedge funds have recently added to or reduced their stakes in LQDA. Globeflex Capital L P bought a new position in shares of Liquidia during the 2nd quarter valued at about $175,000. Nykredit A S bought a new stake in Liquidia in the 2nd quarter worth approximately $177,000. Fluent Financial LLC purchased a new stake in Liquidia in the second quarter worth approximately $287,000. WINTON GROUP Ltd purchased a new stake in Liquidia in the second quarter worth approximately $335,000. Finally, Fulcrum Equity Management bought a new position in Liquidia during the second quarter valued at approximately $399,000. Institutional investors own 64.54% of the company’s stock.

More Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: A valuation analysis argues that Liquidia could be substantially undervalued, potentially by as much as 74%, if YUTREPIA retains meaningful market access despite the patent dispute. The analysis highlights the company’s commercial revenue potential and ongoing investor interest. Liquidia Could Be 74% Undervalued
• Positive Sentiment: Analyst coverage remains constructive. HC Wainwright reiterated a Buy rating and a $58 price target, well above the recent trading level, while another report described Liquidia among bullishly viewed healthcare stocks. Analysts Are Bullish on Liquidia
• Neutral Sentiment: Institutional ownership data showed more funds adding than reducing positions in the latest quarter, including substantial purchases by BlackRock and T. Rowe Price. However, insider activity was heavily weighted toward sales, which may temper that signal.
• Negative Sentiment: A federal court found two patent claims valid and infringed in connection with YUTREPIA’s use for pulmonary hypertension associated with interstitial lung disease. Liquidia plans to remove that indication from the product label, raising concerns about access, future revenue and the company’s prior forecast of more than $1 billion in 2027 net revenue. Liquidia Falls as Patent Ruling Overhang Continues
• Negative Sentiment: Several law firms announced shareholder investigations seeking potential securities claims tied to the patent ruling and Liquidia’s revenue projections. Such notices can increase litigation uncertainty and add selling pressure. Levi and Korsinsky Liquidia Investigation
• Negative Sentiment: HC Wainwright reduced its EPS forecasts across 2026–2030, including Q3 2026 EPS to $0.76 from $1.01 and FY2026 EPS to $2.72 from $3.44. The firm maintained its Buy rating, but the cuts reflect greater uncertainty around YUTREPIA’s earnings potential. HC Wainwright Liquidia Earnings Estimates

Analyst Ratings Changes

A number of research firms have recently commented on LQDA. Royal Bank Of Canada set a $130.00 price objective on shares of Liquidia in a research report on Friday, July 24th. Lifesci Capital lowered shares of Liquidia from an “outperform” rating to a “hold” rating and set a $90.00 target price on the stock. in a report on Wednesday, August 12th. BTIG Research cut shares of Liquidia from a “buy” rating to a “neutral” rating in a research note on Thursday, October 1st. Stephens set a $130.00 price target on shares of Liquidia in a report on Friday, July 24th. Finally, Wall Street Zen lowered shares of Liquidia from a “buy” rating to a “hold” rating in a research report on Saturday. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $83.69.

Liquidia Company Profile

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).